Johnson & Johnson (NYSE:JNJ) is in talks to buy Synthes Inc. for $20 billion, according to a report in the Wall Street Journal.
The Journal, citing anonymous sources with knowledge of the situation, reported late Friday that the New Brunswick, N.J.-based conglomerate had made an overture to buy the Swiss medical device giant in a deal that could be worth $20 billion. However, the paper’s source cautioned that the deal was still “fragile” and could fall apart at any time.
Synthes, which makes bone screws, rods and power tools used in surgery, pulled in just under $3.7 billion in sales last year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The deal, should it come to fruition, would be the largest in the history of JNJ. It is also the second rumored mega-deal the company has been involved with this year.
In January, JNJ was supposedly kicking the tires on an $11.3 billion buyout of Smith & Nephew (NYSE:SNN). The rumored deal, which was reported in the The Telegrath newspaper, was promptly swatted down by SNN officials.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
